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The soluble interleukin 2 receptor (sIL-2R) has been proposed as a marker of disease activ-
ity in patients with sarcoidosis. However, no studies have evaluated whether serum sIL-2R
measurement is of use in establishing the diagnosis of sarcoidosis in patients who are sus-
pected of sarcoidosis among other diseases.
Methods
A cohort study was conducted, consisting of new patients who visited the immunology out-
patient clinic and whose serum sIL-2R levels were available before a definitive diagnosis
was established between February 2011 and February 2016. All patients underwent stan-
dard diagnostic testing for sarcoidosis (e.g. laboratory tests, radiographic and/or nuclear
imaging and/or affected site biopsy). This resulted either in the diagnosis of sarcoidosis or
the exclusion of sarcoidosis with the diagnosis of another disease. Results of sIL-2R and
angiotensin-converting enzyme (ACE) levels, radiographic and nuclear imaging and histol-
ogy results were collected and definitive diagnoses were recorded. Sensitivity, specificity,
the concordance statistic from the receiver operating characteristic curve and Youden’s
Index were calculated to assess the performance of sIL-2R in the diagnosis of sarcoidosis
and were compared to ACE, currently one of the most used diagnostic biomarkers in the
diagnosis of sarcoidosis.
Results
In total 983 patients were screened for inclusion, of which 189 patients met the inclusion
criteria. A total of 101 patients were diagnosed with sarcoidosis after diagnostic workup, of
whom 79 were biopsy-proven. In 88 patients a diagnosis other than sarcoidosis was made.
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The sensitivity and specificity of serum soluble interleukin 2 receptor levels to detect sar-
coidosis were 88% and 85%. The sensitivity and specificity of ACE were 62% and 76%.
Receiver operating characteristic curve analysis revealed that sIL-2R receptor is superior to
ACE (p<0.0001).
Conclusion
Serum sIL-2R is a sensitive biomarker and superior to ACE in establishing the diagnosis of
sarcoidosis and can be used to rule out sarcoidosis in patients suspected of sarcoidosis.
1. Introduction
Sarcoidosis is a multisystem disease of unknown origin, characterized by non-caseating granu-
lomas, which can affect almost any organ system. The diagnosis of sarcoidosis is based on
clinical and radiographic manifestations and histopathologic detection of non-caseating gran-
ulomas in the affected organ, after exclusion of other diseases that may present similarly. [1]
Diagnostic tests that can contribute to the diagnosis of sarcoidosis include serum angiotensin-
converting enzyme (ACE), conventional chest radiograph, high-resolution chest computed
tomography (CT), broncho-alveolar lavage and fluorodeoxyglucose-positron emission tomog-
raphy (FDG-PET).[2] Undetected sarcoidosis can lead to substantial morbidity. [3, 4]Although
ACE is one of the most used diagnostic biomarkers for sarcoidosis, it lacks sensitivity. [5] High
sensitivity is needed when a test is used in the initial diagnostic workup, especially when this
test is used to rule out the disease.
One of the main immunologic features of sarcoidosis is the influx of CD4+ T-helper (Th)1
cells at sites of active disease. [6] Th 1 cells secrete interleukin (IL) 2, which promotes T-cell
proliferation and survival. [7] IL-2 acts via the IL-2 receptor, which consists of the common γ
chain (CD132), a β chain (CD122) and an α chain (CD25). CD25 is overexpressed by activated
T-cells and regulatory T-cells and can be secreted from the cell membrane in a soluble form;
also referred to as soluble IL-2R (sIL-2R.) Hence, sIL-2R is a surrogate marker for T-cell acti-
vation. Peripheral blood sIL-2R levels thus reflect the level of T cell activation in an individual
and elevated blood sIL-2R levels correlate with disease activity, for instance in patients with
rheumatoid arthritis, systemic lupus erythematosus or IgG4-related disease, but also in sar-
coidosis patients. [8–12]
There are various theories on the biological action of sIL-2R in the immunopathology of
inflammatory diseases. One of the proposed mechanisms of action is that sIL-2R competes
with activated T-cells for available IL-2 and thereby inhibits T-cell proliferation. [13, 14]
Another proposed function is that sIL-2R binds IL-2, thereby prolonging IL-2 half-life, which
enhances its immune-stimulatory effects. [15, 16] On the other hand, it has been proposed
that IL-2 can be presented to CD4+ T-cells via the sIL-2R-IL-2 complex, thereby upregulating
FOXP3 expression and differentiation into T regulatory cells that subsequently control
immune activity. [17]
Up to now, it is unclear whether sIL-2R is produced to combat the sarcoidosis-associated
immune activation or whether it has an active role in the pathogenesis of sarcoidosis. It is
clear, however, that there is a correlation between sIL-2R and sarcoidosis. Earlier research
showed a correlation between sIL-2R and disease activity, the extent of disease and response
to treatment. [11, 18–23] In two studies which specifically examined patients with ocular sar-
coidosis, serum sIL2-R has been proposed as a diagnostic biomarker. [24, 25] Another study,
sIL-2R in the diagnosis of sarcoidosis
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conducted in patients with sarcoid skin lesions demonstrated a correlation between serum
sIL-2R levels and the number of involved organs. [26] However, no study has evaluated
whether the measurement of serum sIL-2R can be useful in diagnosing systemic sarcoidosis in
symptomatic patients, whose diagnosis is still uncertain. Thus it remains unknown, whether
serum sIL-2R, apart from being a biomarker for disease activity, can be used as a diagnostic
tool for sarcoidosis in clinical practice. We hypothesized that serum sIL-2R is a sensitive and
specific diagnostic biomarker that can differentiate between sarcoidosis and non-sarcoidosis
patients in a cohort of patients suspected of sarcoidosis.
To test this, we conducted a cohort study consisting of new patients in whom sarcoidosis
was suspected, but not yet proven or disproven and whose sIL-2R levels were measured before
a diagnosis of sarcoidosis or another disease was established. In this cohort, after diagnostic
workup and after a definitive diagnosis (sarcoidosis or another disease) was established, we cal-
culated the sensitivity and specificity of sIL-2R in the diagnosis of sarcoidosis and defined the
optimal cut-off value and compared this to serum ACE levels.
2. Material and methods
2.1 Study population
In this study, we included patients visiting the immunology outpatient clinic, in which sar-
coidosis, among other diseases, was a part of the differential diagnosis and of whom serum
sIL-2R levels were measured before the definitive diagnosis of sarcoidosis or another disease
was established. Sarcoidosis was suspected when a patient was referred to the Immunology
department with one or more of these symptoms: 1) lung complaints, i.e. shortness of breath,
persistent dry cough or chest pains; 2) uveitis or inflammation of the lacrimal glands; 3) skin
disorders, i.e. erythema nodosum, lupus pernio, infiltration of scars or tattoo; 4) neurological
complaints, i.e. hearing loss, facial nerve palsy or epilepsy; 5) polyarthritis; 6) incidental find-
ing of lymphadenopathy on imaging.
Medical records of patients, whose serum sIL-2R level was assessed at the Erasmus MC
between February 2011 and February 2016, were screened for potential inclusion in our study.
The following inclusion criteria were applied: availability of medical records, sarcoidosis as
part of the differential diagnosis, availability of serum sIL-2R value before a definitive diagnosis
was established and a finished diagnostic workup at the immunology outpatient department
(Fig 1). Exclusion criteria were: an established diagnosis of sarcoidosis before serum sIL-2R
measurement and immunosuppressive medication within the two weeks prior to sIL-2R
measurement or use of ACE inhibitors one month prior to ACE measurement. Patients who
received immunosuppressive medication were excluded, because immunosuppressive medica-
tion can reduce sIL-2R levels. [11, 27] The diagnosis of sarcoidosis relies on consistent clinical
and radiological features and histological demonstration of non-caseating granulomas in the
affected organ(s), according to the American Thoracic Society/European Respiratory Society/
World Association of Sarcoidosis and other Granulomatous Disorders (ATS/ERS/WASOG)
guidelines. [28] In our Sarcoidosis Expertise Centre, sarcoidosis is diagnosed according to
these criteria and the diagnosis is verified by at least one pulmonary specialist and at least one
clinical immunologist. Patients without histological confirmation of sarcoidosis were, in addi-
tion to the evaluation by a pulmonary specialist and a clinical immunologist, evaluated by a,
for sIL-2R and ACE blinded, pulmonary specialist who assessed clinical information, radio-
logic and nuclear imaging. When categorized as sarcoidosis or very probable sarcoidosis the
patient was included in the group of patients with a definitive diagnosis of sarcoidosis. Other-
wise, the patient was included as a non-sarcoidosis patient.
sIL-2R in the diagnosis of sarcoidosis
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The ACE measurement of the date closest to the date of the first sIL-2R measurement was
used. If the ACE measurement was performed more than one month prior to or more than
one month after sIL-2R measurement, serum ACE was regarded as not available.
Demographic data and anatomical localization of sarcoidosis disease activity were recorded.
Four anatomical localizations of sarcoidosis activity were distinguished in this study: sarcoidosis
Fig 1. Flowchart of study design and inclusion of patients. � sIL-2R: soluble interleukin 2 receptor. �� ROC: receiver
operating characteristic curves
https://doi.org/10.1371/journal.pone.0223897.g001
sIL-2R in the diagnosis of sarcoidosis
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with predominantly lung, ocular, neurological or skin involvement. Multiple organ involve-
ment could be present within one patient. Additionally, when sarcoidosis was an incidental
finding on radiographic imaging, performed for other reasons, with no organ-related symp-
toms, none of these categories was chosen. Data on chest radiograph, chest CT and FDG-PET
scan were collected. Chest radiographs were scored using the Scadding scale. [29]
The serum sIL-2R levels of 101 anonymous blood bank donors were used as healthy controls.
Strengthening the reporting of observational studies in epidemiology guidelines were used
to structure the reporting of this observational study.[30] The use of laboratory investigation
to gather non-identifiable data in this observational study adheres to the tenets of the Declara-
tion of Helsinki. The medical ethical committee of Erasmus University Medical Center
approved the protocol and the associated procedures.
2.2 Analysis of serum parameters
Serum sIL-2R measurements were performed (ELISA; Diaclone, Besancon Cedex, France) at
the laboratory medical immunology at Erasmus MC. A serum sIL-2R value<2500 pg/mL is
considered as not elevated within the Erasmus MC, which is based on values sIL-2R levels
measured in 101 healthy blood donors. Serum ACE levels were determined by kinetic assay
(Bu¨hlmann Laboratories, Switzerland), with reference range�68 U/mL.
2.3 Sample size calculation
Hypothetical confidence intervals were calculated using Buderer’s formula. Reaching a confi-
dence interval of approximately 5% on either side, with a power of 80%, would require 200
patients Therefore, we strived to include 200 patients.
2.4 Statistical analysis
The characteristics of patients with and without the definitive diagnosis of sarcoidosis were
summarized using descriptive statistics, such as medians and percentages. Non-parametric
tests were used to compare characteristics between the groups. We calculated the specificity,
sensitivity and the Youden’s index, as well as the concordance statistic (C-statistic), which can
be calculated from the receiver operating characteristic (ROC) curve for all patients. Addition-
ally, we calculated the sensitivity, specificity, Youden’s index and C-statistic for the subgroup
of biopsy-confirmed sarcoidosis patients.
Sensitivity and specificity can be used to calculate the Youden’s index. The Youden’s index
reflects the performance of a dichotomous diagnostic test.
The ROC curve is designed to visualize and detect the optimal performance of a binary test
with a varied cut-off point. The optimal cut-off for sIL-2R was calculated by maximizing sensi-
tivity and specificity, using the values generated by a ROC curve. Kruskal-Wallis one-way
analysis of variance of the data on the localization of sarcoidosis and the levels of sIL-2R was
performed.
The statistical analyses were all done using Excel, IBM SPSS statistics 21.0.0 for Windows
(SPSS inc., Chicago, IL, USA), and R, using the package pROC. [31]
3. Results
3.1 Patient characteristics
Of the 983 screened patients 189 were included and 794 were excluded (Fig 1). The exclusion
was due to unavailable medical records (n = 446), sarcoidosis not in the differential diagnosis
(thus not being suspected of sarcoidosis at all: n = 75), or undocumented differential diagnosis
sIL-2R in the diagnosis of sarcoidosis
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(n = 26). Patients were also excluded when the diagnosis was established prior to serum sIL-2R
measurement (n = 218) or when the diagnostic workup was not finished or finished elsewhere
(n = 7). Furthermore, 22 patients were excluded due to medication use: some patients due to
immunosuppressive medication use prior to serum sIL-2R measurement (n = 14), others due
to ACE inhibitor use prior to serum ACE measurement (n = 8). Of the 189 included patients,
101 patients were finally diagnosed with sarcoidosis, of which 79 were biopsy-confirmed
sarcoidosis patients and another 22 patients without positive biopsy were classified as very
probable sarcoidosis by the blinded reviewer. In 88 patients, sarcoidosis was excluded and
another disease was diagnosed, including Sjo¨gren’s syndrome, tuberculosis, multiple sclerosis
or rheumatoid arthritis. A comprehensive list of all the diagnoses is provided in the footnotes
of Table 1. ACE levels were available in 120 patients.
Demographic characteristics did not differ between the sarcoidosis and non-sarcoidosis
groups (Table 1).
Serum sIL-2R levels are depicted in Fig 2 and presented in Table 1. The median serum sIL-
2R level in patients with a definitive diagnosis of sarcoidosis (n = 101) was 6100 pg/mL, 2600
pg/mL in patients with a definitive diagnosis of another disease(n = 88) and 1515 pg/mL in
healthy controls (n = 101, healthy blood bank donors). The sIL-2R levels were significantly
higher in patients with a definitive diagnosis of sarcoidosis compared to patients with diseases
other than sarcoidosis (P < 0.001). In patients with a definitive diagnosis of granulomatous
diseases, lung diseases, uveitis, infectious diseases or other diseases, sIL-2R levels were higher
than healthy controls (P < 0.001) but lower than sarcoidosis patients (P< 0.001).
Table 1. Patient characteristics.
Definitive sarcoidosis
(n = 101)
Definitive diagnosis other than sarcoidosisb
(n = 88)
Sex, female (% female) 51 (50%) 52 (59%)
Median age at diagnosis, years (IQRa) 43 (35–52) 44 (31–57)
Positive biopsy (n) 79 0
Angiotensin-converting enzyme
median 77 51
IQR a 44–109 31–69
Soluble interleukin 2 receptor
median 6100 2600
IQR a 4500–9850 1925–3300
a IQR: interquartile range
b Including uveitis of unknown origin (n = 19), Nonspecific interstitial pneumonia (n = 3), Systemic lupus
erythematosus (n = 3), Asthma (n = 2), Chronic obstructive pulmonary disease (n = 2), Fatigue of unknown origin
(n = 2), Fibromyalgia (n = 3), Multiple sclerosis (n = 2), Neuromyelitis optica (n = 2), Ocular vasculitis (n = 2),
Rheumatoid arthritis (n = 2), Tuberculosis (n = 2), Sjo¨gren’s syndrome (n = 2), Sudden deafness of unknown origin
(n = 2), Alopecia (n = 1), Arthritis psoriatica (n = 2), Atypical parkinsonism (n = 1), Auto-immune encephalitis
(n = 1), Cervical myelopathy (n = 1), Chronic cough due to reflux (n = 1), Dacryops (n = 1), Epstein Barr viral
infection (n = 1), Erythema nodosum (n = 1), Exertional dyspnea (n = 1), Extrinsic allergic alveolitis (n = 1),
Folliculitis (n = 1), Guillain-Barre syndrome (n = 1), Herpes simplex related apthosis (n = 1), Human
immunodeficiency virus (n = 1), Hyper IgE syndrome (n = 1), Hypophysitis (n = 1), Idiopathic pulmonary fibrosis
(n = 1), Increased intracranial pressure (n = 1), Klebsiella pneumoniae infection (n = 1), Langerhans cell histiocytosis
(n = 1), Lipoma (n = 1), Neuroendocrine tumor (n = 1), Macular retinopathy (n = 1), Nontuberculous
Mycobacterium infection (n = 1), Osteoarthritis (n = 1), Presumed ocular histoplasmosis (n = 1), Rosacea (n = 2),
Schwannoma (n = 1), Scleritis (n = 1), Small fiber neuropathy (n = 1), Stills disease (n = 1), Systemic vasculitis
(n = 1), Toxoplasmosis (n = 1), Ulcerative colitis (n = 1), Urticaria (n = 1), Vitreomacular traction syndrome (n = 1),
Vocal cord paralysis (n = 1)
https://doi.org/10.1371/journal.pone.0223897.t001
sIL-2R in the diagnosis of sarcoidosis
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Of all definitive sarcoidosis patients, 65% had a positive chest radiograph, while 99% had a
positive CT-scan. Of all sarcoidosis patients who underwent a PET-CT scan, 91% had a posi-
tive PET-CT scan. Thirty-five percent of sarcoidosis patients presented with sarcoidosis stage
0 on chest radiograph, while 28% showed stage I, 25% stage II, 10% stage III and only 2%
showed stage IV fibrosis on the chest radiograph.
3.2 Sensitivity, specificity, Youden’s index, and C-statistic
The sensitivity of sIL-2R was superior to ACE (Table 2) in the diagnosis of sarcoidosis. The
Youden’s index performed better for sIL-2R than for ACE (0.73 versus 0.38, respectively). The
ROC curve (Fig 3) depicts the performance of both sIL-2R and ACE. The C-statistic, a measure
of test performance which can be calculated from this curve, is significantly better for sIL-2R
Fig 2. Dot plot of serum soluble interleukin 2 receptor levels in various diseases and healthy controls. �. Four patients have been assigned
towards multiple groups: Two tuberculosis and one extrinsic allergic alveolitis patients were assigned towards lung diseases and granulomatous
diseases. One Patient with toxoplasmosis was assigned towards granulomatous diseases as well as towards infectious diseases.
https://doi.org/10.1371/journal.pone.0223897.g002
Table 2. Sensitivity, specificity, Youden’s index and concordance statistic in the diagnosis of sarcoidosis.




Concordance statisticc (95% CIa)
sIL-2R, cutoff 2500 pg/mL 99% (95–100) 47% (36–57) 0.45 0.91 (0.87–0.96)
sIL-2R, cutoff 3550 pg/mL 88% (82–94) 85% (78–93) 0.73 0.91 (0.87–0.96)
ACE, cutoff 68 U/mL 62% (51–73) 76% (64–88) 0.38 0.68 (0.58–0.78)
sIL-2R, cutoff 3550 pg/mL, biopsy-confirmed sarcoidosis 87% (80–95) 85% (78–93) 0.73 0.93 (0.87–0.98)
ACE, cutoff 68 U/mL, biopsy-confirmed sarcoidosis 60% (48–72) 76% (64–88) 0.36 0.68 (0.50–0.79)
a CI: confidence interval
b Interpretation Youden’s index: A higher Youden’s index is more favorable.
c Interpretation concordance statistic: A higher concordance statistic is more favorable.
https://doi.org/10.1371/journal.pone.0223897.t002
sIL-2R in the diagnosis of sarcoidosis
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(C-statistic = 0,91, with 95% CI 0,87–0,96) versus ACE (C-statistic = 0,68 with 95% CI 0.58–
0.78) (P< 0.001).
The area under the curve (AUC) is a measure of test performance. A larger area under the
curve indicates a better test performance.
When calculating the sensitivity and specificity of serum sIL-2R in a subgroup of patients,
consisting of patients with a definitive diagnosis of biopsy-confirmed sarcoidosis (n = 79) and
patients with a definitive diagnosis other than sarcoidosis (n = 88), the associated sensitivity
and specificity of sIL-2R and ACE similar to the sensitivity and specificity for the whole study
group (Table 2). In this subgroup, the C-statistic remained significantly better for sIL-2R ver-
sus ACE (P = 0.003).
3.3 Correlation of sIL-2R with diagnostic parameters
There is a significant, but rather weak correlation between sIL-2R and chest radiograph stage
(Spearman’s rho 0,24; P = 0.021). Median sIL-2R levels were lower in patients without paren-
chymal involvement (stages 0 and I) as compared to patients with parenchymal involvement
(stages II, III and IV). (Table 3).
Only two patients with a definitive diagnosis of sarcoidosis had no sarcoidosis-associated
signs on CT-scan. Therefore, a correlation between CT positive and negative patients was
not performed. However, the two patients with a negative CT-scan, displayed markedly lower
serum sIL-2R levels (3100 pg/mL and 3700 pg/mL), in comparison to the interquartile range
of patients with a positive CT-scan (5700–7900 pg/mL). Although the sIL-2R value of the two
Fig 3. Receiver operating characteristic curves comparing soluble interleukin 2 receptor levels and angiotensin-
converting enzyme in the diagnosis of sarcoidosis (N = 189). � sIL-2R: soluble interleukin 2 receptor. �� ACE:
angiotensin-converting enzyme
https://doi.org/10.1371/journal.pone.0223897.g003
sIL-2R in the diagnosis of sarcoidosis
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FDG-PET negative sarcoidosis patients was lower (3600 pg/mL and 4600 pg/mL) than the
median sIL-2R value of the FDG-PET positive sarcoidosis patients (5700 pg m/L), the values
were near or within the interquartile range observed of the FDG-PET positive patients (4075–
7900).
3.4 Determining the optimal cutoff of serum sIL-2R to facilitate the
diagnosis of sarcoidosis
The current cut-off used in our hospital to indicate an elevated serum sIL-2R level in an indi-
vidual is 2500 pg/mL and as such was not chosen to facilitate the diagnosis of a certain disease.
This is clearly reflected by the unbalanced specificity sensitivity pattern for sarcoidosis when
this sIL-2R cut-off was applied (Table 2). ROC analysis indicated that a serum sIL-2R value of
3550 pg/ml represents the optimal cut-off for diagnosing sarcoidosis with 88% sensitivity and
85% specificity and a Youden’s Index of 0.73, which is considered good.
Applying this optimal cut-off to the biopsy-confirmed subgroup resulted in similar sensitiv-
ity and specificity and a Youden’s index of 0.73. In order to make a fair comparison, we also
calculated the optimal cut-off point for ACE, using the ROC curve. The optimal cut-off point
for ACE was 68.75, which equals its current cut-off point.
3.5 Serum sIL-2R levels in sarcoidosis subgroups
A trend for a higher median sIL-2R level was observed in case of nervous system involvement,
however, this was not statistically significant (Table 4).
4. Discussion
In this study we demonstrated that serum sIL-2R has high and superior sensitivity and speci-
ficity compared to ACE for diagnosing sarcoidosis in a group of patients, presenting with
Table 3. Diagnostic parameters in sarcoidosis patients.
Number of patients Median sIL-2R levels (IQRb) in pg/mL




hilar or mediastinal nodal enlargement
27 6300 (4854–9100)
Stage 2
nodal enlargement and parenchymal disease
19 10800 (5300–19368)
Stage 3

















a Chest radiograph staging: stage 2 is both nodal enlargement and parenchymal disease, while stage 3 is parenchymal disease without nodal enlargement. Therefore,
stage 2 is widely regarded as more severe than stage 3.
b IQR: interquartile range
https://doi.org/10.1371/journal.pone.0223897.t003
sIL-2R in the diagnosis of sarcoidosis
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symptoms, which raised a suspicion of sarcoidosis as well as other diseases. In patients with a
definitive diagnosis of sarcoidosis, sIL-2R is significantly elevated compared to patients with a
definitive diagnosis of another disease. Thus, in a group of patients who have not yet received
a definitive diagnosis, but are suspected of sarcoidosis, serum sIL-2R is able to discriminate
between patients with and without sarcoidosis.
Sarcoidosis is a heterogeneous systemic disease and notoriously difficult to diagnose. Evalu-
ation often requires extensive diagnostic testing and invasive tests, such as histological sam-
pling of the affected tissue. [2, 32] The ACE, which is widely used as a diagnostic biomarker
for sarcoidosis, has a low sensitivity, ranging from 22–80% that hampers its use in a diagnostic
setting. [5, 24, 33, 34]The sensitivity of 60% observed for ACE in the current study is within
this range. Our study, using robust and frequently used statistical methods such as the C-statis-
tic and Youden’s index, demonstrates that serum sIL-2R is more sensitive and equally specific
as ACE in diagnosis in patients suspected of sarcoidosis. [35–39] The demonstrated superiority
of serum sIL-2R over ACE as a diagnostic tool for sarcoidosis underlines its use as a valuable
clinical instrument in the workup of patients suspected for sarcoidosis and might have conse-
quences for subsequent and potential unnecessary (radiological or invasive) evaluation. [40]
We also observed a significant correlation between serum sIL-2R levels and chest radio-
graph stage. However, this correlation was rather weak (spearman’s’ rho 0.24) and might
therefore not be clinically relevant. Sarcoidosis stage III chest radiograph represents less severe
disease (parenchymal involvement without nodal enlargement) compared to sarcoidosis stage
II chest radiograph (parenchymal involvement in addition to nodal enlargement) and was also
associated with lower levels of serum sIL-2R than radiographic stage II sarcoidosis. Stage IV
disease, which is characterized by pulmonary fibrosis, showed high levels serum of sIL-2R.
However, these levels were lower than serum sIL-2R levels found in patients with stage II dis-
ease, which is associated with nodal and parenchymal involvement. However, stage IV disease
might not necessarily have correlated with disease activity at the time of assessment. Since lung
fibrosis is irreversible, stage IV disease can still be visible on chest radiograph, while sarcoidosis
Table 4. Soluble interleukin 2 receptor levels.
Group Number of persons Median sIL-2R level (pg/mL) IQRa
Healthy controls 101 1515 1150–1880
Sarcoidosis 101 6100 4500–9850
Nervous system 6 16851 5027–11020
Ocular 40 6150 4866–7900
Skin 16 6050 4975–8750
Lung 48 7300 4739–11175
Granulomatous diseasesb 9 3300 3000–3550
Lung diseasesc 11 3000 2400–4700
Infectious diseasesd 7 2300 1900–3200
Uveitis 19 2300 1900–3200
a IQR: interquartile range
b Including Rheumatoid arthritis (n = 2), Tuberculosis (n = 2), Erythema nodosum (n = 1), Extrinsic allergic alveolitis (n = 1), Langerhans cell histiocytosis (n = 1),
Systemic vasculitis (n = 1), Toxoplasmosis (n = 1)
c Including Nonspecific interstitial pneumonia (n = 3), Asthma (n = 2), Chronic obstructive pulmonary disease (n = 2), Tuberculosis (n = 2), Extrinsic allergic alveolitis
(n = 1), Idiopathic pulmonary fibrosis (n = 1)
d Including Epstein Barr viral infection (n = 1), Herpes simplex related apthosis (n = 1), Human immunodeficiency virus (n = 1), Klebsiella pneumoniae infection
(n = 1), Nontuberculous Mycobacterium infection (n = 1), Presumed ocular histoplasmosis (n = 1), Toxoplasmosis (n = 1)
https://doi.org/10.1371/journal.pone.0223897.t004
sIL-2R in the diagnosis of sarcoidosis
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is biochemically and clinically less active. This might explain why the highest values of sIL-2R
were not found in stage IV disease, but rather in stage II.
In the tertiary hospital where this study took place, ACE is less expensive than sIL-2R.
(€10,00 versus €53,57). However, since sIL-2R is very sensitive, one could speculate that other
diagnostic tests, such as CT or FDG-PET might not be necessary for patients with low sIL-2R
values. The associated costs (€250,00 and €800,00 respectively) could perhaps be avoided. We
measured sIL-2R with ELISA, a relatively rapid (5–6 hours) method that requires standard lab-
oratory equipment and can thus easily be implemented in most clinical laboratories. Alterna-
tively, fully automated techniques are also available. [24] A detailed evaluation of the cost-
effectiveness of diagnostic tests used in the diagnostic workup of sarcoidosis is beyond the
scope of this study. Yet whether parameters, such as ACE and FDG-PET screening, are ren-
dered redundant by sIL-2R assessment needs evaluation in a cost-effectiveness study
We demonstrate that the probability of having sarcoidosis with a serum sIL-2R level
of< 3550 pg/mL is low. This optimal cut-off value of 3550 pg/mL results in a good test perfor-
mance, both for sensitivity and specificity when used as a diagnostic biomarker for sarcoidosis.
[41]
Although underpowered and not designed for subgroup analysis, variations in serum sIL-
2R levels between subgroups based on anatomical localization of sarcoidosis disease activity
were observed. This was most evident for patients with neurological involvement, who dis-
played the highest sIL-2R levels. Whether these high serum sIL-2R levels in neurosarcoidosis
reflects the total burden of T-cell activation or is an incidental finding, remains unknown.
There is a high clinical variation in sarcoidosis patients. This might be explained by bio-
chemical or genetic differences. It has been shown that certain human leukocyte antigen alleles
are associated with variations in the clinical manifestations. For example, the DRB1�0301 allele
is associated with Lo¨fgren’s syndrome in a Dutch cohort.[42] Whether genetic variances of
human leukocyte antigen alleles influence the sIL-2R levels is unknown. Further studies specif-
ically designed for this purpose might further elucidate this observation.
A limitation of our study is the number of patients included. However, the number of
included patients (189) did approach our initial sample size calculation of 200 patients. Fur-
thermore, since the effect difference observed in this study between ACE and sIL-2R is larger
than the estimated effect difference used in the sample size calculation, it is easier to detect a
significant difference. Therefore, our study is adequately powered for our primary outcomes.
A strength of our study is the control group of non-sarcoidosis patients. All patients
included in this study were suspected of sarcoidosis at presentation. Therefore, all diseases that
could cause sarcoidosis-like symptoms, ranging from tuberculosis to arthritis psoriatica, are
included in this study. Therefore, we strongly believe that our study approach most optimally
reflects clinical practice
In this study, all sIL-2R levels were measured before the definitive diagnosis was established.
Therefore, the outcome, i.e. the diagnosis of sarcoidosis, has not influenced the measurement
of sIL-2R and prevents bias. [43] For ACE measurements, only one patient had ACE measured
after the diagnosis of sarcoidosis. We feel that this one patient will not have biased the overall
result.
There were no missing values for sIL-2R. There were, however, missing values for ACE.
When we performed a sensitivity analysis in a subgroup of patients that had no missing values
for ACE, sensitivity for sIL-2R was 91% and specificity 85% with a cut-off of>3550 pg/mL.
These numbers are almost identical to those of the whole population (88% and 85% respec-
tively). With this, we can safely assume that the missing data are not related to the outcome
and therefore the whole study population can be used, including patients who have missing
values for ACE.
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The results of this study have limitations in their application to clinical practice, due to the
population in this study, which does not reflect the general population, but rather the popula-
tion in a tertiary hospital. The patients in this study were often referred to the tertiary hospital
due to difficult to diagnose disease.
This study compared patients with a definitive diagnosis of sarcoidosis and patients with
a definitive diagnosis of another disease, not with healthy controls. These patients were diag-
nosed with various diseases and thus represent a heterogeneous group. Comparing the use of
sIL-2R within a diseased population is a comparison that mimics clinical practice more closely
than comparing sarcoidosis patients and healthy controls.
5. Conclusion
In this cohort study consisting of patients in whom sarcoidosis is suspected but not yet proven
or excluded, we demonstrate the superiority of serum sIL-2R above ACE in the screening for
sarcoidosis. Therefore, serum sIL-2R may serve as a diagnostic, discriminating tool and as a
biomarker for patients that are suspected for sarcoidosis. Due to its high sensitivity, sIL-2R can
be a useful tool to rule out sarcoidosis in patients suspected of sarcoidosis.
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